HB 2078
In CommitteeHouse
Medical cannabis
Expanding access to medical cannabis consultants and department of health compliant cannabis product.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
HB 2078 expands access to medical cannabis by creating a new medical cannabis endorsement for retailers and processors, establishing a state database and recognition card system for qualifying patients, and allowing patients to buy immature plants, clones, seeds, and compliant products directly from licensed producers and processors. It also creates a certification program for medical cannabis consultants to assist patients with product selection and use.
- Creates a new medical cannabis endorsement for retailers and processors, allowing them to sell or give away compliant medical cannabis products to qualifying patients and designated providers.
- Establishes a secure, confidential medical cannabis authorization database managed by the Department of Health, which issues recognition cards (valid for 1 year for adults, 6 months for minors) and allows authorized users to verify patient status and track authorizations.
- Creates a medical cannabis consultant certification program, requiring training in medical cannabis science, product knowledge, and safe handling, and allowing consultants to assist patients with product selection and use—though they cannot diagnose or treat medical conditions.
- Expands what qualifying patients and designated providers may purchase: immature plants or clones from producers, cannabis seeds from producers, and compliant cannabis products (tested and labeled per state standards) from processors.
- Sets new licensing and operational rules for cannabis retailers, including a 5-license cap per owner, and a license forfeiture process if a retailer does not open within 9–24 months (with exceptions for local bans or zoning delays).
Who is affected
- Qualifying patients and designated providers — Medical cannabis patients and their designated providers gain expanded access to medical cannabis consultants and compliant products through a new authorization database and recognition cards; they can purchase more types of cannabis products directly from licensed producers and processors, and may receive products at no charge from licensed retailers or processors with medical endorsements.
- Cannabis retailers and processors — Retailers and processors can obtain a medical cannabis endorsement to legally sell or give away compliant medical cannabis products to qualifying patients, and must train staff and use a state database to verify patient authorization and issue recognition cards.
- Medical cannabis consultants — Newly certified medical cannabis consultants—working for licensed retailers, processors, or health care professionals—can provide advice on product selection, administration, and safe handling, but cannot diagnose or treat medical conditions.
- Health care professionals — Health care professionals can enter patients into the state database and issue recognition cards, but are prohibited from authorizing medical cannabis use at retail or processor locations.
- State agencies (Department of Health and Department of Revenue) — The state Department of Health and Department of Revenue gain new responsibilities to develop and maintain a secure database, issue recognition cards, verify tax-exempt sales, and enforce compliance with medical cannabis rules.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Qualifying patients and designated providers may now purchase immature plants, clones, and seeds directly from licensed producers—restoring a long-standing access pathway that was effectively blocked under prior enforcement interpretations. This allows patients (especially those with limited transportation or in rural areas) to grow their own medicine, reducing long-term costs and increasing autonomy over treatment regimens. This directly benefits patients who rely on cost-effective, self-cultivated cannabis for chronic conditions.
HealthcarePeopleRef: Sec. 1(1)(c) and Sec. 5(1)The secure, confidential medical cannabis authorization database with strict privacy safeguards—including nonreversible de-identification, differential privacy, and federal government access restrictions—significantly enhances patient privacy compared to prior paper-based or less-secure systems. This reduces fear of discrimination, stigma, or federal prosecution, encouraging more patients to seek legal medical cannabis access without exposing themselves to unnecessary risk.
Rights & LibertiesPeopleRef: Sec. 3(1)–(3), Sec. 3(9), Sec. 3(12)The medical cannabis endorsement allows retailers and processors to provide compliant products at no charge to qualifying patients—creating a legal pathway for compassionate donations and nonprofit distribution models. This enables community-based support networks (e.g., caregiver collectives, licensed nonprofits) to legally assist vulnerable patients (e.g., low-income, disabled, elderly) without fear of criminal liability, directly expanding access for those who cannot afford commercial products.
HealthcarePeopleRef: Sec. 2(1) and Sec. 2(4)(e)The medical cannabis consultant certification program—requiring training in medical conditions, cannabinoid science, safe handling, and product knowledge—creates a new layer of patient support for navigating complex product choices. While consultants cannot diagnose, their standardized training improves consistency and safety in product selection, especially for patients new to medical cannabis or managing complex regimens. This benefits patients who lack access to cannabis-knowledgeable clinicians.
HealthcarePeopleRef: Sec. 4(1)(d), Sec. 4(2), and Sec. 4(5)(a)(iv)Expanding what patients may purchase to include compliant products from licensed processors (tested, labeled per state standards) ensures that medical patients receive products with verified potency, contaminants, and labeling—reducing exposure to untested or mislabeled products from illicit markets. This enhances product safety and reliability, especially for patients with sensitivities or narrow therapeutic windows (e.g., epilepsy, PTSD).
HealthcareLean peopleRef: Sec. 5(3)
Potential Concerns (5)
The 5-license cap per owner and license forfeiture provisions (no operation within 9–24 months) may reduce market entry for well-resourced multi-state operators seeking scale, but disproportionately burden small operators who lack capital reserves to absorb 9–24 months of non-operational costs; many small operators may be forced to exit the market before generating revenue, consolidating market share among larger players. This provision is not neutral—it creates structural pressure favoring entities with deeper capital buffers, even if phrased as a general licensing rule.
Business & EmploymentPeopleRef: Sec. 1(3)(b) and Sec. 1(3)(c)(ii)A $1 fee per recognition card—while modest—will be collected directly from patients at point of service, effectively creating a user fee for accessing a state-mandated authorization system. Since patients must obtain a recognition card to legally access medical cannabis under the new framework, this fee functions as a de facto access tax; low-income patients (especially seniors or those on fixed incomes) will bear disproportionate burden relative to ability to pay, even if the dollar amount is small.
FinancialLean peopleRef: Sec. 3(10) and Fiscal ImpactRecognition cards for minors expire every 6 months and require reexamination by a health care professional for renewal—creating a higher administrative and time burden for families of minors with chronic conditions. Unlike adult patients, minors cannot renew via compassionate care unless explicitly designated, and the photograph requirement for minors (unless compassionate care applies) adds logistical and privacy concerns for families, potentially disrupting continuity of care for vulnerable pediatric patients.
HealthcareLean peopleRef: Sec. 3(4)(a) and Sec. 3(5)Medical cannabis consultants are prohibited from diagnosing or treating conditions, and training focuses on product knowledge—not clinical decision-making—limiting their ability to assist patients with complex or comorbid conditions. This creates a gap in care for patients whose conditions are not clearly aligned with the list of qualifying debilitating conditions, especially those with overlapping symptoms (e.g., fibromyalgia + depression + insomnia), who may receive incomplete or misaligned guidance from consultants lacking clinical training.
HealthcareLean peopleRef: Sec. 4(2)(a) and Sec. 4(6)(a)The license forfeiture exception for local bans or zoning delays places the burden on retailers to prove that local action—not their own decisions—prevented operation, creating a reactive, case-by-case appeals process that favors municipalities with strong legal departments. This may disincentivize local governments from proactively supporting medical cannabis access, and small retailers in restrictive jurisdictions (e.g., rural counties) may be unable to navigate the appeals process, effectively entrenching local opposition as a barrier to care.
Local GovernmentRef: Sec. 1(3)(c)(v) and Sec. 1(3)(c)(iv)
Who Is Most Affected
Qualifying patients—especially low-income, elderly, or rural residents—benefit significantly from expanded access to affordable, safe, and legally protected medical cannabis. The ability to purchase immature plants/clones/seeds directly from producers and receive products at no charge from licensed entities directly improves affordability and autonomy. Privacy protections reduce stigma and fear of discrimination. However, the $1 card fee and minor-specific renewal burdens may slightly offset gains for vulnerable subgroups.
Cannabis retailers and processors gain new revenue opportunities through the medical endorsement, especially those able to absorb the costs of database integration, consultant training, and compliance. However, the 5-license cap and license forfeiture rules may disadvantage small operators without capital reserves, while the $1,381 annual license fee increase (from prior amounts) raises operating costs across the board. Large, well-capitalized operators benefit more than mom-and-pop shops.
Medical cannabis consultants gain a new, regulated career path with formal training and certification, but their scope is strictly limited to product advice—no diagnosis or treatment. Consultants working for large retailers or health systems gain stability and legitimacy, while self-employed consultants may face challenges building client bases in a new, competitive market. The certification fee and continuing education requirements add ongoing costs.
Health care professionals gain a formal role in authorizing patients for medical cannabis via the state database, but are prohibited from authorizing use at retail/processor locations—reinforcing separation between clinical care and product distribution. This may reduce administrative burden for clinics but also limits integration of medical cannabis into standard care pathways. The $1 fee collection responsibility adds minor administrative tasks.
The Department of Health and Department of Revenue gain new responsibilities (database management, recognition card issuance, tax verification), but the $1 card fee and $1,381 license fee increases provide dedicated revenue to support these functions. The $5,000 fine for database noncompliance creates accountability, but also increases regulatory risk for contractors. Overall, state agencies gain operational capacity and funding, though implementation complexity may strain resources initially.